Supportive Care | Specialty

The OncLive Supportive Care condition center page is a comprehensive resource for clinical news and expert insights on supportive care and management of patients with cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, best practices, and ongoing research as it relates to supportive care for patients with cancer.

Hypomethylating Agents for AML

January 28th 2020

QUAZAR: Oral Azacitidine Maintenance in AML

January 28th 2020

Decision Making on Consolidation Therapy for AML

January 28th 2020

Assessment of Fitness for AML Induction Chemotherapy

January 28th 2020

AML Induction Strategy and Molecular Testing

January 28th 2020

Molecular Testing for AML

January 28th 2020

Dr. Hegazi on Nutrition-Related Toxicities in Oncology

January 23rd 2020

Refaat Hegazi, MD, PhD, MPH, discusses nutrition-related toxicities in oncology.

Patient Tragedy Inspires Program Focused on Immune-Related Toxicities

January 8th 2020

The advent of immunotherapy options to treat patients with cancer has brought with it a new wave of immuno-related toxicities. One institution, Massachusetts General Hospital, has taken steps to establish an immunotherapy toxicity service care team, inspired by a 65-year-old patient with metastatic melanoma that had spread to his lungs and brain.

Cardiac Therapy Improves Heart Function in Patients With Chemotherapy-Induced Events

January 4th 2020

Cardiac resynchronization therapy improved heart function in patients who developed chemotherapy-induced cardiomyopathy.

FDA to Review Eflapegrastim for Chemo-Induced Neutropenia

January 2nd 2020

The FDA has accepted a biologics license application to review eflapegrastim for the management of chemotherapy-induced neutropenia.

Final Thoughts From ASH 2019 in CLL

December 24th 2019

Novel Combinations in Development for CLL

December 24th 2019

PI3K Inhibitors in R/R CLL

December 24th 2019

BTK Inhibitors in R/R CLL

December 24th 2019

Venetoclax in R/R CLL

December 24th 2019

Progression on Frontline Ibrutinib in CLL

December 24th 2019

Resistance Mechanisms Associated With BTK Inhibitors

December 24th 2019

Ibrutinib + Venetoclax for Frontline CLL

December 24th 2019

MRD Testing for CLL

December 24th 2019

Obinutuzumab + Venetoclax for Frontline CLL

December 24th 2019